Actively Recruiting
Led by Institute of Tropical Medicine, Belgium · Updated on 2025-05-02
1000
Participants Needed
2
Research Sites
N/A
Total Duration
I
Institute of Tropical Medicine, Belgium
Lead Sponsor
U
University of Manitoba
Collaborating Sponsor
Researchers are studying how monkeypox (mpox) spreads in the Democratic Republic of Congo (DRC), how it affects different groups of people, and how well vaccines protect against it. This observational study uses a cross-sectional survey design, collecting data from patients diagnosed with mpox at one point in time, and a case-control approach comparing those who test positive to those who test negative to find risk factors and vaccine effectiveness. The study is conducted by the Institut National de Recherche Biomédicale and international partners, focusing on provinces heavily affected by mpox outbreaks. Participants with suspected mpox who visit hospitals or health centers for testing will be invited to join the study. They will answer questions about symptoms, medical history, exposure to the virus, and vaccination status. Biological samples such as blood, throat swabs, and skin lesion swabs will be collected to test for mpox and other infections like measles or chickenpox. Hospitalized patients will have additional data recorded about their recovery. During the study, researchers will collect clinical and sociodemographic information, exposure factors, and transmission modes of mpox. They will compare infection rates between vaccinated and unvaccinated people and examine differences between two virus types. The study also tracks co-infections and risk factors for severe disease or death. Data will help train healthcare workers and improve real-time sharing on an online platform. The study will run for two years, assessing many health and transmission outcomes related to mpox.
CONDITIONS
Epidemiological and Pathophysiological Insights Through a Cross-sectional Survey (EPIC)
You may qualify if you...
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single point in time
Participants diagnosed with mpox or testing negative will provide information about their symptoms, medical history, and exposure to the virus, and biological samples will be collected for analysis.
1 visit (in-person)
Duration - Up to 2 years
Participants will be observed over time to understand the clinical manifestations, transmission, and outcomes of mpox.
Follow-up assessments as appropriate
Total: 2 locations
1
Masina Mpox Treatment Center
Kinshasa, Masina, Democratic Republic of the Congo
Not Yet Recruiting
2
Masina Mpox Treatment Center
Kinshasa, Democratic Republic of the Congo
Actively Recruiting
L
Laurens Liesenborghs, MD, PhD
S
Sarah Houben, PhD
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Isabel Brosius, Emmanuel Hasivirwe Vakaniaki, Guy Mukari...
https://pubmed.ncbi.nlm.nih.gov/39892407